Study: Diffuse Large B-Cell Lymphoma Patients May Benefit from Involvement in Decision Making

Due to varied periods of decline among patients, previous research indicates that it is difficult to develop treatment options for patients who have relapsed DLBCL. This holds true especially when…

Continue Reading Study: Diffuse Large B-Cell Lymphoma Patients May Benefit from Involvement in Decision Making
Diffuse Large B-Cell Lymphoma: Combination Treatment Superior to Systemic Therapy in Retrospective Study
source: unsplash.com

Diffuse Large B-Cell Lymphoma: Combination Treatment Superior to Systemic Therapy in Retrospective Study

According to a story from Cancer Network, the results of a recent retrospective study have found that a two-part combination treatment for diffuse large B-cell lymphoma (DLBCL), a rare cancer,…

Continue Reading Diffuse Large B-Cell Lymphoma: Combination Treatment Superior to Systemic Therapy in Retrospective Study
Survival for Young Patients with Diffuse Large B-Cell Lymphoma Improved by Ibrutinib
source: pixabay.com

Survival for Young Patients with Diffuse Large B-Cell Lymphoma Improved by Ibrutinib

According to a recent article, new evidence shows adding ibrutinib to a patient’s chemotherapy regimen may improve the longevity of younger patients with diffuse large B-cell lymphoma (DLBCL). Diffuse Large…

Continue Reading Survival for Young Patients with Diffuse Large B-Cell Lymphoma Improved by Ibrutinib
DPX Delivery Platform Could Improve Care For Many Rare Cancers
source: pixabay.com

DPX Delivery Platform Could Improve Care For Many Rare Cancers

IMV Inc. recently presented two posters at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics showcasing their DPX delivery platform's immunotherapeutic capabilities. IMV Inc. IMV Inc. is…

Continue Reading DPX Delivery Platform Could Improve Care For Many Rare Cancers

My Genetically Altered Life: How CAR-T Transformed My Life with Diffuse Large B-Cell Lymphoma

Written by Robyn Stacy-Humphries Wolverine, Spiderman, Wonder Woman, and Deadpool - superheroes most of us love. Why? They have superpowers and escape death by some type of genetic alteration. Humans…

Continue Reading My Genetically Altered Life: How CAR-T Transformed My Life with Diffuse Large B-Cell Lymphoma
Phase 2 Trial Results Show Loncastuximab Tesirine as Beneficial for DLBCL
biker_becca / Pixabay

Phase 2 Trial Results Show Loncastuximab Tesirine as Beneficial for DLBCL

In the Phase 2 LOTIS-2 clinical trial, researchers evaluated the safety, efficacy, and tolerability of Loncastuximab tesirine for patients with aggressive diffuse large B-cell lymphoma (DLBCL). While there are treatment…

Continue Reading Phase 2 Trial Results Show Loncastuximab Tesirine as Beneficial for DLBCL
Phase 3 Trial for Non-Germinal Center Diffuse Large B-Cell Lymphoma is Still Enrolling Patients
source: pixabay.com

Phase 3 Trial for Non-Germinal Center Diffuse Large B-Cell Lymphoma is Still Enrolling Patients

A Phase 3 clinical trial for Non-Germinal Center Diffuse Large B-Cell Lymphoma in patients where it was previously untreated have just announced they are still recruiting participants. The trial is…

Continue Reading Phase 3 Trial for Non-Germinal Center Diffuse Large B-Cell Lymphoma is Still Enrolling Patients
First Patient Dosed in Trial Evaluating Tafasitamib, Lenalidomide, R-CHOP for DLBCL
[Source: pixabay.com]

First Patient Dosed in Trial Evaluating Tafasitamib, Lenalidomide, R-CHOP for DLBCL

For many patients with diffuse large B-cell lymphoma (DLBCL), one first-line treatment is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, even aggressive chemotherapy is not always enough for patients…

Continue Reading First Patient Dosed in Trial Evaluating Tafasitamib, Lenalidomide, R-CHOP for DLBCL
Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma
source: pixabay.com

Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma

  A recent announcement by Gilead Company citing data from Kite Pharma, one of its premier companies, set out remarkable results from Kite’s Zuma-1 clinical trial. The findings confirmed that…

Continue Reading Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma

FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time

  The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…

Continue Reading FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time
Company Releases Early Clinical Data For Experimental Blood Cancer Drug
SarahMarciano / Pixabay

Company Releases Early Clinical Data For Experimental Blood Cancer Drug

According to a story from pm360online.com, the biopharmaceutical company miRagen Therapeutics, Inc., recently presented Phase I clinical trial data regarding the company's experimental drug cobomarsen. This data was presented at…

Continue Reading Company Releases Early Clinical Data For Experimental Blood Cancer Drug